Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Markets around the world, including the US and China, all took a big drop during the uncertainty surrounding President ...

The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Top Create Biotech has filed for an initial public offering. The biotechnology company said Wednesday that it intends to list shares under the ticker symbol TCBG on the Nasdaq Capital Market. Top ...

According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 13.11%, which ...

Recursion Pharmaceuticals RXRX is redefining the traditional model of drug discovery by harnessing the power of artificial intelligence (AI) through its proprietary RecursionOS platform, developed in ...

Real-time index price for S&P 500 Consumer Staples [Sector] (SRCS), along with buy or sell indicators, analysis, charts, ...

AbbVie had a rough Thursday, with its stock tumbling throughout the session and closing near the day’s lowest point. The ...

Vor Biopharma, (NYSE:VOR)  listed on the NYSE Composite, is part of the biotechnology space and has recently garnered ...

In general, analysts remain optimistic regarding the stock, with price targets ranging between $11 and $12 per share. Just recently, analysts at Goldman Sachs reviewed the generic drug industry and ..

Oric Pharmaceuticals is not currently offering a proper buying opportunity. See if the stock goes on to build a base that could spark a new run. The company reported 0% earnings g ...